HealthDay News — Juvéderm Voluma XC is feasible and seems safe for correcting infraorbital hollows, according to a study published online April 5 in JAMA Facial Plastic Surgery.

Michael B. Hall, MD, from the Buckingham Center for Facial Plastic Surgery in Austin, Texas, and colleagues conducted a retrospective observational study involving patients aged 21 to 85 years who underwent Juvéderm Voluma XC treatment to correct infraorbital hollows as a singular intervention. The intervention was an injection of Juvéderm Voluma XC to the tear trough, nasojugal fold, and/or palpebromalar groove. In total, 202 eyes in 101 patients were treated and followed up for a mean of 12 months. 

Related Articles

The researchers found that the average initial treatment volume was 1mL, with 18 patients requiring additional treatment within 3 months. The average time to additional treatment was 35.7 days. Adverse effects included bruising, contour irregularities, swelling, and Tyndall effect, and these occurred in 10, 2, 3, and 1% of patients, respectively. Three patients required hyaluronidase. After treatment 41% of patients completed the FACE-Q Satisfaction With Eyes survey, and 42% of patients completed the FACE-Q Satisfaction With Decision survey. Based on both FACE-Q scores, the overall mean patient satisfaction was 71.1 and 65.6%, respectively.

“Juvéderm Voluma XC has a high patient satisfaction profile and an acceptable safety profile for the correction of infraorbital hollowing,” the authors write.

Abstract/Full Text